Drug profile · INN
tafasitamab
MINJUVI
tafasitamab (MINJUVI) is a b-lymphocyte antigen cd19 binding agent.
EMA: approved Antineoplastic and immunomodulating agents (L01) L01FX12
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — tafasitamab
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 5
- Data quality
- 0.83
Quick answer
tafasitamab (MINJUVI) is a b-lymphocyte antigen cd19 binding agent.
Key facts
INN tafasitamab
Brand MINJUVI
Mechanism B-lymphocyte antigen CD19 binding agent
Target B-lymphocyte antigen CD19
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01FX12
Mechanism of action
B-lymphocyte antigen CD19 binding agent
Primary target: B-lymphocyte antigen CD19
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tafasitamab?
tafasitamab (MINJUVI) is a b-lymphocyte antigen cd19 binding agent.
What is the brand name for tafasitamab?
MINJUVI is a marketed brand name for tafasitamab. Check FDA Drugs@FDA for the current US label holder and prescribing information.